The State of Bangladesh Health

Bangladesh reaches a maternal mortality ratio of 115 per 100,000 live births (WHO MMEIG, 2023) and roughly 98 percent immunization coverage on total health spending near 2.2 percent of GDP (WHO GHED, 2022), a return most peers do not match at this income level. The engine was community delivery, not public money: out-of-pocket payments fund 78 percent of current health expenditure (WHO GHED via World Bank, SH.XPD.OOPC.CH.ZS, 2022) and pushed 6.1 million people into poverty in 2022 (BIDS, HIES 2022). That model has hit its ceiling. Community health workers can promote antenatal visits and distribute oral rehydration salts; they cannot manage diabetes, hypertension, or cervical cancer, which is where the disease burden has moved. The answer is not more of the same delivery model. It is to pool financing, build a mid-level clinical cadre, and make the private majority provider accountable, before LDC graduation raises the cost of the medicines the system runs on.

Executive summary

• Out-of-pocket spending sits at 78 percent of current health expenditure (WHO GHED via World Bank, SH.XPD.OOPC.CH.ZS, 2022), the highest in South Asia after Afghanistan, and pushed 6.1 million people (3.7 percent of the population) into poverty in 2022 (BIDS, HIES 2022).
• Maternal mortality has fallen to 115 per 100,000 live births (WHO MMEIG, 2023) from 523 in 2000, but remains 64 percent above the SDG 3.1 ceiling of 70, with progress concentrated where skilled birth attendance reaches.
• The WHO UHC Service Coverage Index stands at 52 out of 100 in 2021 and 54 in 2023, behind India at 67, Vietnam at 71, and Sri Lanka at 72 in the 2021 vintage.
• LDC graduation on 24 November 2026 (WTO smooth-transition window to November 2029) raises input-cost exposure for a domestic industry that meets 98 percent of local drug demand under the TRIPS waiver (World Bank/IFC, 2021).

Financing is the binding constraint, not delivery

The 78 percent out-of-pocket share (WHO GHED, 2022) is the system's central failure. It is regressive, it deters care-seeking, and it converted illness into impoverishment for 6.1 million people in 2022 (BIDS, HIES 2022). Total health spending of roughly 2.2 percent of GDP (WHO GHED, 2022) sits well below the 5 percent benchmark widely treated as the floor for an adequately financed system, and the publicly financed share is small, so the cost lands on households at the point of care, mostly for secondary and tertiary services that community clinics do not cover.

This is a known, documented gap, not a new diagnosis. Bangladesh's own Health Care Financing Strategy 2012-2032 set out to expand social protection for health and explicitly proposed designing and implementing a Social Health Protection Scheme toward universal coverage (Health Care Financing Strategy 2012-2032, Health Economics Unit). The shortfall is execution, not analysis. Until risk is pooled, supply-side expansion alone will not reduce financial catastrophe, because the catastrophic costs are concentrated in the inpatient and chronic-care episodes that remain almost entirely out-of-pocket.

The disease burden has outrun the delivery model

The maternal and child health victories came from a delivery system optimised for episodic, infectious, and obstetric care. The burden has shifted to chronic non-communicable disease that requires continuous management, diagnostics, and medicines the lower tiers cannot supply. Maternal mortality at 115 (WHO MMEIG, 2023) is far below the 523 of 2000 but still 64 percent over the SDG target of 70, and the remaining deaths cluster where skilled birth attendance and emergency obstetric referral do not reach: rural-urban disparity and attendant-coverage gaps are the proximate drivers. A UHC Service Coverage Index of 52 in 2021 (WHO GHO), trailing India (67), Vietnam (71), and Sri Lanka (72), is the single number that captures the mismatch: coverage breadth has stalled because the services people now need most are the ones the system is least built to deliver.

LDC graduation tightens the medicine supply chain

Bangladesh's pharmaceutical industry meets 98 percent of local demand (World Bank/IFC, Gearing Up for the Future of Manufacturing in Bangladesh, 2021), a strategic asset built under the TRIPS pharmaceutical waiver for least-developed countries. Graduation on 24 November 2026, with a WTO smooth-transition window to November 2029, narrows that latitude: active pharmaceutical ingredient imports and patent exposure both rise unless trade negotiations secure transition safeguards. A financing system that already leaves 78 percent of spending out-of-pocket has little headroom to absorb higher medicine costs, which makes the financing reform and the trade transition two halves of the same problem rather than separate files.

Recommendations

1. Health Economics Unit and Ministry of Finance: stand up the pooled Social Health Protection Scheme already on the books. The 2012-2032 strategy proposed it; the task now is to launch it, starting with the bottom two wealth quintiles and an essential-medicines list that includes NCD drugs. Expected effect: a measurable decline in the out-of-pocket share (WHO GHED SH.XPD.OOPC.CH.ZS) from its 2022 level of 78 percent and fewer of the 6.1 million annual poverty events. Success signal: enrolment of the bottom two quintiles and a first downward print in the OOP series within three GHED release cycles.
2. DGHS and the Ministry of Health: create a licensed mid-level provider cadre tied to mandatory rural service. Pair a chronic-disease-management clinical grade at upazila level with a service obligation for medical graduates, backed by hardship allowances. Expected effect: NCD case-management capacity at the tier community health workers structurally cannot cover, pushing capability past Dhaka. Success signal: a rising upazila-level share of hypertension and diabetes patients under continuous management, and a narrowing rural-urban gap in the UHC index above its 2023 value of 54.
3. DGDA and Ministry of Health: make private-facility accreditation and antibiotic stewardship a condition of operating license. A private sector that delivers a majority of care without mandatory accreditation makes any system-level protocol unenforceable. Require accreditation above clinic scale and prescription-only dispensing for systemic antibiotics, enforced through DGDA pharmacy inspection. Success signal: published share of licensed private facilities holding current accreditation, and a falling rate of over-the-counter systemic-antibiotic sales in DGDA inspection audits.
4. Commerce Ministry and Ministry of Health: fold the pharmaceutical transition into LDC graduation negotiations now. Secure the longest feasible API and patent transition terms before the WTO smooth-transition window closes in November 2029, so the financing reform is not undercut by an external cost shock to the 98 percent domestic supply base. Success signal: agreed transition terms on file before the 2029 deadline and a stable domestic-supply share through graduation.

What would change this view

If the pooled scheme is launched and out-of-pocket spending begins falling toward South Asian norms, the financing diagnosis softens and the priority shifts to delivery-cadre execution. Conversely, if fiscal compression pushes public health spending lower in real terms, out-of-pocket reliance and poverty incidence worsen and the case for pooling becomes more urgent, not less. The strongest counterargument is that demand-side pooling without supply-side capacity simply inflates prices at unaccredited facilities; that is why the cadre and accreditation levers are conditions for the financing reform to work, not alternatives to it. Revised WHO GHED, MMEIG, or UHC vintages that materially move the 78 percent out-of-pocket figure or the UHC index would reset the ranking against regional peers and should be checked against each new release.